News

After setbacks for Roche and Sanofi, AZ scores oral SERD win
AstraZeneca seems to have dodged the problems besetting other developers of oral selective oestrogen receptor degrader (SERD) drugs with a phase 2 win for its candidate camizestrant in a ph